REG - Imaging Biometrics - Vivan Therapeutics and IB Announce Partnership

Imaging BiometricsAnnouncement

03/10/2025 12:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251003:nRSC0412Ca&default-theme=true

RNS Number : 0412C  Imaging Biometrics Limited  03 October 2025

 

Imaging Biometrics Limited

("IB" or the "Company")

 

Vivan Therapeutics and Imaging Biometrics Announce Strategic Partnership to
Advance Gallium Maltolate for New Cancer Indications

 

The collaboration leverages innovative in vivo whole animal high-throughput
drug screening platform to explore new anti-cancer uses of Gallium Maltolate

 

Imaging Biometrics®, LLC, (IB) a Wisconsin-based biotechnology company, and
Vivan Therapeutics, a UK leader in personalized cancer medicine, today
announces a strategic research and commercial partnership to evaluate gallium
maltolate in new oncologic indications.

 

Under the agreement, Imaging Biometrics will supply gallium maltolate, with
support from its trusted partner, Gallixa®, LLC, for evaluation using Vivan's
proprietary in vivo avatar cancer models. These highly customized models
mirror a broad spectrum of tumor molecular profiles and are tested through
Vivan's state-of-the-art high-throughput platform, enabling rapid and scalable
assessment of investigational compounds.

 

Gallium maltolate, a compound that has already shown promise in glioblastoma,
will now be evaluated across a broad spectrum of tumor molecular profiles. The
initial focus will be on colorectal cancer, while also extending to other
challenging malignancies, including pancreatic, lung, and additional
gastrointestinal cancers. The goal is to identify its therapeutic activity
either as a single agent or in combination with existing drugs, potentially
expanding its clinical utility.

 

With the Phase 1 trial in oral gallium maltolate (GaM) for adult glioblastoma
now closed, Imaging Biometrics is evaluating next steps for clinical
development. In parallel, the company is advancing preclinical research
through Vivan Therapeutics' innovative fruit fly screening platform, which
enables rapid assessment across diverse cancer types.

 

"This partnership with Vivan Therapeutics marks an exciting new chapter in the
exploration of gallium maltolate's therapeutic potential," said Michael
Schmainda, CEO of IB. "Their unique fruit fly screening platform enables
rapid, personalized testing that could accelerate the path to more effective
cancer treatments involving GaM."

 

Laura Towart, CEO of Vivan Therapeutics, added: "We're pleased to employ our
proprietary screening platform to assess gallium maltolate's potential across
different cancer profiles. Our ultra-customized in vivo assays have
consistently revealed promising therapeutic options, and we look forward to
uncovering new possibilities for this compound in solid tumors."

 

The collaboration also establishes a framework for future joint development
efforts, particularly around combination therapies. If the screening
identifies compelling opportunities, both companies have agreed to pursue
further co-development discussions.

 

--ENDS--

 The Directors of the Company accept responsibility for the contents of this
announcement.

 For further information, please contact:

 Imaging Biometrics Ltd

 Trevor Brown/Al Musella/Brett Skelly/Michael Schmainda

 Tel: 020 7469 0930
 AlbR Capital Limited (Broker)

 Tel: 020 7220 9797

 

About Imaging Biometrics LLC: IB is a wholly owned subsidiary of Imaging
Biometrics Limited, (LON: IBAI), and focuses on delivering quantitative
imaging platforms and therapeutics that transform how clinicians diagnose and
treat patients more efficiently and effectively. For more information about
IB, visit the company's website at www.imagingbiometrics.com. Follow IB on X,
@ImgBiometrics.

 

About Vivan Therapeutics

Vivan Therapeutics is a precision oncology company delivering personalized
treatment recommendations for cancer patients. Founded on technology developed
at the Icahn School of Medicine at Mount Sinai (NY), Vivan's proprietary
platform maps the full spectrum of tumor-driving genetic alterations and
recreates them in ultra-customized fruit fly in vivo models. This enables
rapid, high-throughput screening of thousands of approved and investigational
drugs, alone or in combination, to identify the most effective therapies for
each individual.

Beyond patient care, Vivan's platform supports biopharma partners in drug
discovery and development. By tailoring investigational treatments to specific
genetic signatures, the technology provides unprecedented opportunities for
patient stratification and precision-driven clinical trial design. The same in
vivo high-throughput platform is also applied across a range of genetic
diseases, advancing discovery internally and in collaboration with global
biopharma clients.

For general information, visit www.vivantx.com .

 

Media Contacts:

Imaging Biometrics, LLC

Michael Schmainda

+1 262-439-8252

mike@imagingbiometrics.com

 

Vivan Therapeutics

Laura Towart

+44 7496375189

laura@vivantx.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRFXLFBEBLFFBE